|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||139.37 - 142.90|
|52 Week Range||101.58 - 147.72|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||30.81|
|Earnings Date||May 8, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||146.83|
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price increase onRead More...
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CRL are favorable, with net inflows of $3.86 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
Charles River Laboratories International, Inc. announced today that it will present at two upcoming investor conferences, including:
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
CRL looks strong and probably capable of further gains but in the short-run we could see a pullback.
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The latest earnings announcement Charles River Laboratories International, Inc. (NYSE:CRL)Read More...
Moody's Investors Service commented that Charles River Laboratories International, Inc's (Charles River) announcement that it has agreed to acquire European-based Citoxlab for a purchase price of $510 million is credit negative because it will increase its financial leverage. There is no impact on Charles River's ratings, including its Ba2 Corporate Family Rating or stable rating outlook. For additional information please refer to Moody's Issuer Comment on Charles River Laboratories International, Inc. available on www.moodys.com.
Using immense amounts of data, AI not only has clinical applications — as in diagnosing patients — but can also be harnessed for behind-the-scenes uses, such as making the development of new drugs more efficient.
Charles River (CRL) delivered earnings and revenue surprises of 7.19% and 1.94%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.21. Earnings, adjusted for one-time gains and costs, were $1.49 per share. The results exceeded Wall Street expectations. ...
– Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Billion –
Charles River Laboratories International, Inc. (CRL) announced today that it has signed a binding offer to acquire Citoxlab for €448 million in cash (or approximately $510 million based on current exchange rates), subject to customary closing adjustments. With operations in Europe and North America, the proposed acquisition of Citoxlab would further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which would enhance the Company’s ability to partner with clients across the drug discovery and development continuum. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “The proposed acquisition of Citoxlab would expand and solidify Charles River’s position as the partner of choice for our clients’ early-stage research needs, at a time when we believe there continues to be significant demand for outsourced services from both biotechnology and pharmaceutical companies.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jim Cramer interviews Charles River Laboratories CEO James Foster about how biotech and pharma are helping more drugs get to market and expansion in China.